NASDAQ : CORT

Corcept Therapeutics Incorporated

$91.12 USD

-$4.24 (-4.45%)

Volume
1.2M
Average Volume
1.14M
Market Capitalization
$9.78B
P/E Ratio
202.49
Dividend Yield
0.00%
Price Target
$91.50
Year High
$97.63
Year Low
$28.66
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.86
Company Overview

NASDAQ

Joseph K. Belanoff

Medical - Pharmaceuticals

Healthcare

CORT

730

US

USD

https://www.corcept.com

650 327 3270

218352102

0001088856

Liquidity Metrics

0.02

2.86

2.77

0.73

0.00

Sales & Valuation

$761.41M

12.72

14.92

81.66

1.15

Profitability

$0.82

$99.65M

6.23%

1.58%

7.50%

5.88%

P/E Metrics

202.49

-3.14

-3.14

Analyst Price Target & Rating

$91.50

$135.00

$50.00

Neutral

3/5

26 Analysts

-0.42%

Financial Health Scores

37.17

5/9

$276.85M

$814.88M

$176.89M

$12.13M

Key Metrics (TTM)

$10.14B

13.18

716.16

2.86

7.50%

-1.23%

0.48%

1.17%

$7.94

-535 days

Company Executives
Name Title
Sean Maduck President of Endocrinology
Joseph K. Belanoff Co-Founder, President, Chief Executive Officer & Director
Atabak Mokari Chief Financial Officer & Treasurer
Amy Flood Chief Human Resources & Communications Officer
Hazel Hunt Chief Scientific Officer
William Guyer Chief Development Officer
Gary Charles Robb Chief Business Officer & Secretary
Joseph Douglas Lyon Chief Technology & Accounting Officer
Monica Tellado President of Emerging Markets
Roberto W. Vieira President of Oncology
Poll Results

No votes yet today — be the first to share your view!

About Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also inves ... tigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?

2026-07-23 10:41:18

Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

2026-07-22 16:05:00

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN.

These major drug stocks rally after Trump's zero tariff announcement

2026-07-22 06:31:14

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

2026-07-21 07:57:01

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

2026-07-20 20:18:52

The transaction involved 40,000 shares with an estimated value of $3.5 million on the July 15, 2026 transaction date. The activity was executed through the conversion of 40,000 options at $19.26 and $23.06 per share, which were immediately liquidated.

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

2026-07-20 20:08:29

The transaction involved the sale of 10,000 shares at $88.30 per share, resulting in a total value of $883,000 on July 15, 2026. The sale reduced the insider's total indirect equity holdings by 0.67%.

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

2026-07-12 15:06:35

The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

2026-07-10 12:06:21

Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.

Frequently Asked Questions

What is the current Corcept Therapeutics Incorporated (CORT) stock price?

Corcept Therapeutics Incorporated(NASDAQ:CORT) stock price is $91.12 in the last trading session. During the trading session, CORT stock reached the peak price of $97.63 while $28.66 was the lowest point it dropped to. The percentage change in CORT stock occurred in the recent session was --4.45% while the dollar amount for the price change in CORT stock was -$4.24.

CORT's industry and sector of operation?

The NASDAQ listed CORT is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of CORT?

Sean Maduck | President of Endocrinology
Joseph K. Belanoff | Co-Founder, President, Chief Executive Officer & Director
Atabak Mokari | Chief Financial Officer & Treasurer
Amy Flood | Chief Human Resources & Communications Officer
Hazel Hunt | Chief Scientific Officer

How many employees does CORT have?

Number of CORT employees currently stands at 730. CORT operates from 101 Redwood Shores Parkway, Redwood City, CA 94025, US.

Link for CORT official website?

Official Website of CORT is: https://www.corcept.com

How do I contact CORT?

CORT could be contacted at phone #650 327 3270 and can also be accessed through its website. CORT operates from 101 Redwood Shores Parkway, Redwood City, CA 94025, US.

How many shares of CORT are traded daily?

The average number of CORT shares traded daily for last 3 months was 1.14M.

What is the market cap of CORT currently?

The market value of CORT currently stands at $9.78B with its latest stock price at $91.12